Department Of Cardiology 4
151. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
152. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
153. Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
154. Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
155. Mortality and Morbidity in Adults with Rheumatic Heart Disease
156. Mortality and Morbidity in Adults with Rheumatic Heart Disease
157. Mortality and Morbidity in Adults with Rheumatic Heart Disease
158. Cardiovascular Disease Burden in Rural Central Asia: A Systematic Review of Epidemiological Trends and Mortality Patterns
159. Features of the course of myocardial infarction in the elderly
160. Frailty in elderly patients with acute myocardial infarction
161. Sex-Specific Trends and Predictors of Outcomes in Acute Myocardial Infarction in Almaty, Kazakhstan
162. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
163. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
164. Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
165. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
166. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
167. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
168. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
169. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
170. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
171. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
172. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
173. Global epidemiology of heart failure
174. RETRACTED: Citrus genus and its waste utilization: A review on health-promoting activities and industrial application
175. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
176. Amiodarone-Induced Angioedema
177. Side effects and efficacy of low-dose amiodarone in rhythm disorders
178. Subclinical Hypothyroidism After a Three-Month Course of Low-Dose Amiodarone
179. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE v survey in 16 European countries
180. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE v survey in 16 European countries
181. Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction
182. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study
183. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study
184. An Integrative Machine Learning Model for Predicting Early Safety Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation
185. Evaluating the Impacts of Procedural and Patient-Specific Factors on the Outcomes of Transcatheter Aortic Valve Implantation (TAVI)
186. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
187. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
188. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
189. European Society of Cardiology Core Curriculum for cardio-oncology
190. European Society of Cardiology Core Curriculum for cardio-oncology
191. European Society of Cardiology Core Curriculum for cardio-oncology
192. European Society of Cardiology Core Curriculum for cardio-oncology
193. European Society of Cardiology Core Curriculum for cardio-oncology
194. European Society of Cardiology Core Curriculum for cardio-oncology
195. European Society of Cardiology Core Curriculum for cardio-oncology
196. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
197. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
198. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
199. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
200. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
1 2 3 4 5 6 9